Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

Fig. 2

Clinical response by assessment tool and presence of somatization comorbidity phenotype (SCP). a Proportion of Routine Assessment of Patient Index Data 3 (RAPID3) and Clinical Disease Activity Index (CDAI) respondersa at week 12. b Proportion of patients assigned to RAPID3 and CDAI with Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28(ESR)) low disease activity (LDA) at week 12. c Proportion of patients with DAS28(ESR) LDA at week 52. d Proportion of RAPID3 and CDAI week 12 respondersa with DAS28(ESR) LDA at week 52. Full analysis set. LDA was defined as DAS28(ESR) ≤ 3.2. aRAPID3 response was defined as ≤ 6 or 20% improvement from baseline, and CDAI response was defined by ≤ 10 or 20% improvement from baseline. Missing data were handled by non-responder imputation

Back to article page